IFC Advisory is delighted to be working with Midatech Pharma (LSE AIM: MTPH; NASDAQ: MTP) Midatech is an R&D company focused on delivering innovative oncology and rare disease products to patients. The Company is developing a range of improved chemo-therapeutics or new immuno-therapeutics, using its three-proprietary platform drug delivery technologies, all of which are in the clinic.
Client Appointment
Midatech Pharma Appointment
22
Mar
Mar
Entertainment AI appoints IFC Advisory
Entertainment AI (AIM: EAI), has appointed IFC as its financial public relations and investor relations [...]
Dec
Bould Opportunities appointment
Bould Opportunities (AIM: BOU) have appointed IFC as their financial public relations and investor relations [...]
Nov
Vordere appointment
IFC has been appointed by Vordere (LSE:VOR), to handle their financial public relations and investor [...]
Oct